SARS-COV-2 Neutralizing IgG Antibodies in Patients Recovered from COVID-19 in a Hospital-Based Study: From Predictions to Reality
Background: The duration and immunity nature in form of antibodies to COVID-19 is still not clear. But so far we know that an immune response protects the individuals from future illness for some specific time. The presence or absence of immunity tells us about the future transmission of illness.
- To determine the frequency of antibodies to COVID-19 after three weeks of negative PCR report.
- To predict the association of the antibodies values with severity of the disease the patient had in recent past.
Material and methods: We did a cross sectional study in department of Pathology on 36 patients recovered from COVID-19 from 3rd July 2020 to 31st July 2020. Antibodies level was measured by electro-chemiluminescence immunoassay using Roche Cobas E411 Chemistry Analyzer for which commercial kits of Roche diagnostics were used as per the instructions of the manufacturer, in respondents after 3 weeks of a negative PCR report.
Results: The mean with standard deviation for numerical variables i.e. (age and antibodies) was 34+11 years and 34.52+12.71 respectively. 29(80.55%) were males and 7(19.45%) females. The mean antibodies level was statically significantly higher in patients with age less than 50 years (p-value: 0.01). Patients who had severe symptoms at time of being reported positive by PCR had significantly higher antibodies cut off values as compared to asymptomatic positive patients (p-value:0.04). Clinically sever Covid-19 patients positively moderates with an increase in the values of the post infection anti SARS-COV-2 antibodies supported by an interaction term with (β=0.388**; ΔR²=0.126, p-value=0.02). Male gender supported by the results of an interaction term with (β=0.388**; ΔR²=0.126, p-value=0.02) had sever disease as compared to female.
Conclusion: The higher anti SARS-COV-2 antibodies were reported in patients with age <50 years and in patients who had severe symptoms or history of hospitalization during the infectious period. There was a statistically significant relationship supported by the interactions terms of higher post infection antibodies level with male gender, an increase in age and with history of sever disease or hospitalization.
1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13
2. WHO, Coronavirus disease 2019 (COVID-19): Situation report—86. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200415-sitrep-86-covid-19.pdf?sfvrsn=c615ea20_6 Date: April 15, 2020, Date accessed: April 16, 2020
3. "Coronavirus in Pakistan - Confirmed Cases". www.covid.gov.pk/. Retrieved 24 July 2020.
4. Godlee F. The burning building. BMJ m1101 (2020) doi:10.1136/bmj.m1101 [CrossRef] [Google Scholar] [Ref list]
5. Ni, L., et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity https://doi.org/10.1101/2020.03.17.20037713 (2020).
6. Liu A, Wang W, Zhao X, et al. Disappearance of antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery [published online ahead of print, 2020 Jul 9]. Clin Microbiol Infect. 2020;S1198-743X(20)30411-0. doi:10.1016/j.cmi.2020.07.009.
7. Kellam P., Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020 In press. [Google Scholar] [Ref list]
8. Kissler S.M., Tedijanto C., Goldstein E. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368(6493):860–868.
9. Bwire GM. Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? [published online ahead of print, 2020 Jun 4]. SN Compr Clin Med. 2020;1-3. doi:10.1007/s42399-020-00341-w.
10. Fanfan Zeng, Chan Dai, Pengcheng Cai, Jinbiao Wang, Lei Xu, Jianyu Li, Guoyun Hu, Lin Wang. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between gender. Jour Med Virol : doi: 10.1002/jmv.25989
11. Khan H. Letter to Editor - Impact of Age Factor in Covid-19 Infectivity in Population of Nowshera KP, Pakistan. World Family Medicine. 2020; 18(5): 75-76
12. Li H, Wang S, Zhong F, et al. Age-Dependent Risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China. Front Med (Lausanne). 2020;7:190. Published 2020 Apr 30. doi:10.3389/fmed.2020.00190
13. CDRH . 2020. FDA. Contains Nonbinding Recommendations This document supersedes "Policy for Diagnostics Testing in Laboratories Certified to Perform High-Complexity Testing under Clinical Laboratory Improvement Amendments (CLIA) prior to Emergency Use Preface Public Comment. [Google Scholar] [Ref list]
14. Li Z., Yi Y., Luo X., Xiong N., Liu Y., Li S. Development and clinical Application of A rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020 doi: 10.1002/jmv.25727.
15. Khan, H., Hussain, S., zar, A., fawad, S. Analysis of demographic variables in acquiring infection and mortality due to COVID-19.. Microbes and Infectious Diseases, 2020; 1(2): 70-76. doi: 10.21608/mid.2020.34444.1030
16. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, Hu G, Wang L: A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between gender. medRxiv preprint 2020. [PMC free article] [PubMed] [Google Scholar] [Ref list].
17. Lin Q, Zhu L, Ni Z, Meng H, You L. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection [published online ahead of print, 2020 Mar 25]. J Microbiol Immunol Infect. 2020;S1684-1182(20)30075-X. doi:10.1016/j.jmii.2020.03.015
18. Wang D, Hu B, Hu C et al Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‐infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061
19. Hou H, Wang T, Zhang B, et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunology. 2020;9(5):e01136. Published 2020 May 6. doi:10.1002/cti2.1136
Copyright (c) 2021 Hamzullah Khan, Fazli Bari, Tahir Mohammad, Rizwanullah Jan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All research articles published in the Journal of Rawalpindi Medical College (JRMC) are fully open access: immediately freely available to read, download, and share. Copyrights of all articles published in JRMC are retained by the authors. First publication rights are granted to JRMC. The journal/publisher is not responsible for subsequent uses of the work.
All articles are published under the Creative Commons Attribution (CC BY-SA 4.0) license.